Four uncommon clinical fungi, Lodderomyces elongisporus, Kodamaea ohmeri, Cyberlindnera fabianii and Wickerhamomyces anomalus, isolated in superficial samples from Côte d'Ivoire.


Journal

Journal de mycologie medicale
ISSN: 1773-0449
Titre abrégé: J Mycol Med
Pays: France
ID NLM: 9425651

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 16 01 2023
revised: 31 05 2023
accepted: 19 06 2023
medline: 28 8 2023
pubmed: 26 6 2023
entrez: 25 6 2023
Statut: ppublish

Résumé

The rare yeast species Lodderomyces elongisporus, Kodamaea ohmeri, Cyberlindnera fabianii, and Wickerhamomyces anomalus are increasingly implicated in severe mycoses in immunocompromised patients. This study aimed to assess the prevalence of uncommon yeast species in Côte d'Ivoire. The yeast isolates from superficial samples, mainly vaginal swabs, were collected at the Pasteur Institute of Abidjan in a study on the molecular epidemiology of clinical yeast species. Identification relied on MALDI-TOF MS and ITS sequence analysis. Antifungal susceptibility testing was performed using the CLSI method. Of the 315 strains analysed from 227 outpatients, 14 belonged to 4 uncommon species: Lodderomyces elongisporus, Kodamaea ohmeri, Cyberlindnera fabianii, and Wickerhamomyces anomalus. None exhibited elevated fluconazole, amphotericin B, caspofungin, ketoconazole, or flucytosin MIC. The presence of these rare yeasts represents a risk in immunocompromised people. Their adequate and timely identification is a priority. Overall, enhancing the mycoses diagnostic capacities in Côte d'Ivoire, and more generally in African clinical laboratories with limited resources is a critical aim.

Identifiants

pubmed: 37356368
pii: S1156-5233(23)00054-9
doi: 10.1016/j.mycmed.2023.101410
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101410

Informations de copyright

Copyright © 2023 SFMM. Published by Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflicts of interest.

Auteurs

Ama Valérie Bonouman Ira (AVB)

UMI 233, TransVIHMI, UM-IRD-INSERM U1175, Laboratoire de Parasitologie Mycologie, Faculté de Pharmacie, Université de Montpellier, Montpellier 34090, France; Institut Pasteur de Côte d'Ivoire, BP 490, Abidjan, Cote d'Ivoire. Electronic address: ama.bonouman@etu.umontpellier.fr.

Donika Krasteva (D)

UMI 233, TransVIHMI, UM-IRD-INSERM U1175, Laboratoire de Parasitologie Mycologie, Faculté de Pharmacie, Université de Montpellier, Montpellier 34090, France.

Francis Kouadjo (F)

Institut Pasteur de Côte d'Ivoire, BP 490, Abidjan, Cote d'Ivoire.

Fréderic Roger (F)

UMI 233, TransVIHMI, UM-IRD-INSERM U1175, Laboratoire de Parasitologie Mycologie, Faculté de Pharmacie, Université de Montpellier, Montpellier 34090, France.

Virginie Bellet (V)

UMI 233, TransVIHMI, UM-IRD-INSERM U1175, Laboratoire de Parasitologie Mycologie, Faculté de Pharmacie, Université de Montpellier, Montpellier 34090, France.

David Koffi (D)

Institut Pasteur de Côte d'Ivoire, BP 490, Abidjan, Cote d'Ivoire.

Cyrille Pottier (C)

UMI 233, TransVIHMI, UM-IRD-INSERM U1175, Laboratoire de Parasitologie Mycologie, Faculté de Pharmacie, Université de Montpellier, Montpellier 34090, France.

Offianan André Toure (OA)

Institut Pasteur de Côte d'Ivoire, BP 490, Abidjan, Cote d'Ivoire.

Pascal Drakulovski (P)

UMI 233, TransVIHMI, UM-IRD-INSERM U1175, Laboratoire de Parasitologie Mycologie, Faculté de Pharmacie, Université de Montpellier, Montpellier 34090, France.

Aliko Joseph Djaman (AJ)

Institut Pasteur de Côte d'Ivoire, BP 490, Abidjan, Cote d'Ivoire.

Stéphane Ranque (S)

Institut Hospitalo-Universitaire Méditerranée Infection,Marseille 13005 , France; IRD, AP-HM, SSA, VITROME, Aix-Marseille Université, Marseille 13007, France.

Sébastien Bertout (S)

UMI 233, TransVIHMI, UM-IRD-INSERM U1175, Laboratoire de Parasitologie Mycologie, Faculté de Pharmacie, Université de Montpellier, Montpellier 34090, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH